Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 6.65
(-8.65%)
SEK 6.65
(-8.65%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 108.6 Million SEK | 3922.22% |
| 2022 | 2.7 Million SEK | -34.97% |
| 2021 | 4.15 Million SEK | -11.03% |
| 2020 | 4.66 Million SEK | 3888.89% |
| 2019 | 117 Thousand SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 119.2 Million SEK | 9.76% |
| 2024 Q2 | 110.5 Million SEK | -7.3% |
| 2023 Q1 | 3.8 Million SEK | 40.74% |
| 2023 Q3 | 2.7 Million SEK | -18.18% |
| 2023 Q2 | 3.3 Million SEK | -13.16% |
| 2023 Q4 | 108.6 Million SEK | 3922.22% |
| 2023 FY | 108.6 Million SEK | 3922.22% |
| 2022 Q3 | 1.5 Million SEK | -56.0% |
| 2022 FY | 2.7 Million SEK | -34.97% |
| 2022 Q4 | 2.7 Million SEK | 80.0% |
| 2022 Q1 | 3.78 Million SEK | -8.91% |
| 2022 Q2 | 3.4 Million SEK | -9.86% |
| 2021 Q1 | 4.51 Million SEK | -3.19% |
| 2021 Q3 | 4.51 Million SEK | -7.44% |
| 2021 FY | 4.15 Million SEK | -11.03% |
| 2021 Q4 | 4.15 Million SEK | -8.12% |
| 2021 Q2 | 4.88 Million SEK | 8.06% |
| 2020 FY | 4.66 Million SEK | 3888.89% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | 4.66 Million SEK | 0.0% |
| 2020 Q2 | - SEK | -100.0% |
| 2020 Q1 | 29 Thousand SEK | -75.21% |
| 2019 Q1 | 117 Thousand SEK | 0.0% |
| 2019 FY | 117 Thousand SEK | 0.0% |
| 2019 Q4 | 117 Thousand SEK | 0.0% |
| 2019 Q3 | 117 Thousand SEK | 0.0% |
| 2019 Q2 | 117 Thousand SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -574.66% |
| Ziccum AB (publ) | 857 Thousand SEK | -12572.112% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -2081.161% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -343.483% |
| Genovis AB (publ.) | 79.32 Million SEK | -36.914% |
| Intervacc AB (publ) | 181 Thousand SEK | -59900.0% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -426.903% |
| Active Biotech AB (publ) | 3 Million SEK | -3520.0% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | -80.094% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -2072.0% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | -52.082% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -1287.328% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -25513.208% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -3437.459% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -4109.302% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -10760.0% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 88.909% |
| Camurus AB (publ) | 24.5 Million SEK | -343.139% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -293.964% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 87.471% |
| Cyxone AB (publ) | 858 Thousand SEK | -12557.343% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -6247.165% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | -195.045% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -16206.306% |
| SynAct Pharma AB | 637 Thousand SEK | -16948.666% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -12676.471% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -6066.951% |
| BioInvent International AB (publ) | 23.24 Million SEK | -367.217% |
| Alzinova AB (publ) | 800 Thousand SEK | -13475.0% |
| Oncopeptides AB (publ) | 106.48 Million SEK | -1.984% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -13947.705% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | -19.683% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -254.069% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 53.084% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -10135.627% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |